title: Differential prefrontal gray matter correlates of treatment response to fluoxetine or cognitive-behavioral therapy in obsessive-compulsive disorder.
abstract: Nearly one-third of patients with obsessive-compulsive disorder (OCD) fail to respond to adequate therapeutic approaches such as serotonin reuptake inhibitors and/or cognitive-behavioral therapy (CBT). This study investigated structural magnetic resonance imaging (MRI) correlates as potential pre-treatment brain markers to predict treatment response in treatment-naïve OCD patients randomized between trials of fluoxetine or CBT. Treatment-naïve OCD patients underwent structural MRI scans before randomization to a 12-week clinical trial of either fluoxetine or group-based CBT. Voxel-based morphometry was used to identify correlations between pretreatment regional gray matter volume and changes in symptom severity on the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS). Brain regional correlations of treatment response differed between treatment groups. Notably, symptom improvement in the fluoxetine treatment group (n=14) was significantly correlated with smaller pretreatment gray matter volume within the right middle lateral orbitofrontal cortex (OFC), whereas symptom improvement in the CBT treatment group (n=15) was significantly correlated with larger pretreatment gray matter volume within the right medial prefrontal cortex (mPFC). No significant a priori regional correlations of treatment response were identified as common between the two treatment groups when considering the entire sample (n=29). These findings suggest that pretreatment gray matter volumes of distinct brain regions within the lateral OFC and mPFC were differentially correlated to treatment response to fluoxetine versus CBT in OCD patients. This study further implicates the mPFC in the fear/anxiety extinction process and stresses the importance of lateral portions of the OFC in mediating fluoxetine's effectiveness in OCD. Clinical registration information: http://clinicaltrials.gov-NCT00680602.
authors: Department and Institute of Psychiatry, University of São Paulo Medical School, São Paulo, Brazil. mqhoexter@gmail.com
authors: Marcelo Q
authors: MQ
authors: Hoexter
authors: Darin D
authors: DD
authors: Dougherty
authors: Roseli G
authors: RG
authors: Shavitt
authors: Carina C
authors: CC
authors: D'Alcante
authors: Fabio L S
authors: FL
authors: Duran
authors: Antonio C
authors: AC
authors: Lopes
authors: Juliana B
authors: JB
authors: Diniz
authors: Marcelo C
authors: MC
authors: Batistuzzo
authors: Karleyton C
authors: KC
authors: Evans
authors: Rodrigo A
authors: RA
authors: Bressan
authors: Geraldo F
authors: GF
authors: Busatto
authors: Euripedes C
authors: EC
authors: Miguel
mesh_terms: D000328:Adult; D001284:Atrophy / Q000473:pathology; D015928:Cognitive Behavioral Therapy; D005260:Female; D005473:Fluoxetine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D036421:Nerve Fibers, Unmyelinated / Q000473:pathology*; D059906:Neuroimaging; D009483:Neuropsychological Tests; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy / Q000473:pathology* / Q000628:therapy*; D011237:Predictive Value of Tests; D017397:Prefrontal Cortex / Q000187:drug effects / Q000473:pathology*; D011615:Psychotherapy, Group; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D005473:Fluoxetine; D017367:Selective Serotonin Reuptake Inhibitors